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Editorial Comment
Flecainide for Pediatric
Arrhythmias   Do Children
Behave Like Little Adults?*
ANDREW E. EPSTEIN, MD, FACC
Birmingham, Alabama
Flecainide acetate is approved for the treatment of life-
threatening ventricular arrhythmias in adults . Although rec-
ognized as effective treatment for supraventricular arrhyth-
mias, it has not received approval for this indication .
Furthermore, the package insert warns that the safety and
efficacy of flecainide in children < 18 years old has not been
established . Thus, Perry et al . (1) have advanced our under-
standing of the drug's usefulness and pharmacology . Of the
63 patients studied, 5  were !518 years old . Particularly
gratifying responses were seen in the treatment of the
permanent form of junctional reciprocating tachycardia,
atrial ectopic tachycardia and chaotic atrial tachycardia .
Eighteen of 25 patients with accessory connections achieved
either full or partial control of their arrhythmia . A remark-
able 100% responsiveness was seen in the 10 patients with
ventricular tachycardia. Not only did the drug prove effica-
cious, but also it was remarkably devoid of adverse drug
effects including the precipitation of life-threatening proar-
rhythmic events and congestive heart failure .
How are children different from adults? Garson (2) has
called attention to important changes of the autonomic
nervous system, gastric secretion, gastric motility, protein
binding and drug metabolism that occur during maturation .
Furthermore, the mechanisms and substrates of arrhyth-
mias, and therefore drug responsiveness, differ in children
and adults . For example, atrial tachycardia caused by ab-
normal automaticity occurs commonly in children (3) but
only rarely in adults (4) . Whereas ventricular tachycardia in
children is often idiopathic (5,6) or caused by cardiac tumors
(7) and congenital heart disease (8), coronary artery disease
is by far the most common underlying substrate in older
patients .
Perry et al . (1) have reiterated Garson's prior suggestion
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(2) that drug dosages be based on the adult dose normalized
for body surface area . This recommendation is founded on
observations that the intestinal surface area, total body
water, cardiac output, hepatic blood flow and renal function
all influence serum drug levels and each also varies directly
with the body surface area . Nevertheless, Perry et al . show
that a wide range of flecainide dosage regimens (5  to 225
mg/m2 per day) were required to achieve therapeutically
effective serum trough levels even though dosing was based
on scaled down adult doses . Measurement of serum levels of
flecainide is therefore important to evaluate drug doses in
children .
A notable difference between children and adults in this
series is the low incidence of proarrhythmia . Indeed, it was
seen only in individuals with accessory atrioventricular
connections, and no life-threatening proarrhythmia occurred
in any patient. Furthermore, because these patients presum-
ably had normal left ventricular function, the absence of
proarrhythmia in the study patients with left ventricular
dysfunction is of even more interest . Adult cardiologists
have learned that adverse cardiac events from flecainide are
related to both the type of ventricular arrhythmia being
treated ( ) and the degree of underlying left ventricular
dysfunction (10) . One explanation for the absence of life-
threatening proarrhythmia or of heart failure observed by
Perry et al . (I) is that few of their patients had left ventricular
dysfunction . Most had supraventricular tachycardia and 8 of
the 10 patients with ventricular tachycardia had well pre-
served left ventricular function . Thus, the relative safety of
flecainide observed by Perry et al . should not lull clinicians
into complacency when treating children who have lethal or
potentially lethal arrhythmias with this drug, especially if left
ventricular dysfunction is present . In addition, the respon-
siveness of the one child with a suspected myocardial
hamartoma should not be construed to suggest responsive-
ness in all such patients, as the authors warn in their
discussion .
How should efficacy be assessed? Perry et al . (1) report
that the mean flecainide trough levels in patients with full
and partial arrhythmia control were 0.36 and 0.41 Ag/ml,
respectively, which are somewhat lower than the target
levels often used in the treatment of adult patients . It must
be recognized, however, that previously reported therapeu-
tic ranges were usually determined during treatment of
adults with ventricular rather than supraventricular arrhyth-
mias. Because the majority of the young patients treated by
Perry et al . had the latter type of arrhythmia, direct compar-
ison is difficult . Furthermore, Woosley (11) has wisely
warned that use of the term "therapeutic range" may be
misleading because there is great variability in the blood
concentration required for drug efficacy and that the deter-
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mination of efficacy should be measured in conjunction with
the patient's clinical response, electrocardiographic (ECG)
monitoring, exercise testing and programmed stimulation .
For patients with arrhythmias that are not life-threatening .
ECG and ambulatory monitoring techniques are particularly
appropriate . Because flecainide causes important widening
of the PR and QRS intervals (1), the ECG is useful to assess
when electrophysiologic effects are occurring (12) . By virtue
of its noninvasive nature . noninvasive monitoring is partic-
ularly attractive for the follow-up of young patients .
How desirable is long-term drug therapy for young pa-
tients? Especially for the young. commitment to long-term
drug therapy may be less desirable than a curative proce-
dure. For many arrhythmias, ablation by either catheter or
surgical techniques is especially effective . Catheter ablation
has been used to treat ventricular tachycardia (13), reentrant
atrioventricular tachycardia utilizing both right- and left-
sided accessory connections (14), atrial tachycardia (15) and
most recently bundle branch reentrant (16) and atrioventric-
ular nodal reentrant (17) tachycardias . However, surgery is
especially effective in the treatment of supraventricular
arrhythmias mediated by accessory connections and should
be considered in young patients as an alternative to long-
term drug therapy . Commitment to long-term amiodarone
usage certainly must be considered a less optimal treatment
modality in view of the complications that occur during
long-term use of this agent .
New areas for research . The long-term efficacy of the
treatment of young patients with flecainide is unknown . As
Perry et al . (1) state, further investigation of the pharmaco-
kinetics of flecainide is needed, especially in children < I
year of age. Furthermore, because age alters pharmacoki-
netics, a "therapeutic" dosage at one age may not provide
long-term efficacy if absorption, metabolism and distribution
also change with maturation . One special area of interest will
be the use of flecainide in young patients with left ventricular
dysfunction due to rate-related cardiomyopathies . In these
individuals, drug therapy could potentially be used as a
bridge to achieve either full or parital arrhythmia control and
thereby allow improvement of left ventricular dysfunction
and later surgical cure with lower risk due to improved
hemodynamics . However, the risk of flecainide use in pa-
tients with overt heart failure cannot be advised . Finally, the
development of new drugs with a longer half-life, wider
dosing interval and less toxicity will be welcomed .
Conclusions . Given the difficulty of performing clinical
investigations in young patients because of the problems of
consent, compliance and changing pharmacokinetics with
age, Perry et al . (1) are to be commended for their careful
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study . Their work not only extends prior studies by demon-
strating the usefulness of flecainide in the treatment of both
supraventricular and ventricular arrhythmias in young pa-
tients, but also provokes interesting questions for further
study in arrhythmia treatment of these individuals .
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